Description

Simple

A medication used to treat certain cancers.

Clinical

A vinca alkaloid used to treat acute leukemia, malignant lymphoma, Hodgkin's disease, acute erythraemia, and acute panmyelosis.

Overview

Vincristine is an antitumor vinca alkaloid isolated from Vinca Rosea. It is marketed under several brand names, many of which have different formulations such as Marqibo (liposomal injection) and Vincasar. Vincristine is indicated for the treatment of acute leukaemia, malignant lymphoma, Hodgkin's disease, acute erythraemia, and acute panmyelosis. vincristine sulfate is often chosen as part of polychemotherapy because of lack of significant bone–marrow suppression (at recommended doses) and of unique clinical toxicity (neuropathy).

Pharmacology

Indication

Treatment of acute lymphocytic leukemia (ALL), Hodgkin lymphoma, non-Hodgkin lymphomas, Wilms' tumor, neuroblastoma, rhabdomyosarcoma. Liposomal vincristine is indicated for the treatment of relapsed Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL).

Pharmacodynamic

Vincristine is a vinca alkaloid antineoplastic agent used as a treatment for various cancers including breast cancer, Hodgkin's disease, Kaposi's sarcoma, and testicular cancer. The vinca alkaloids are structurally similar compounds comprised of 2 multiringed units, vindoline and catharanthine. The... Read more

Mechanism of action

The antitumor activity of Vincristine is thought to be due primarily to inhibition of mitosis at metaphase through its interaction with tubulin. Like other vinca alkaloids, Vincristine may also interfere with: 1) amino acid, cyclic AMP, and glutathione metabolism, 2) calmodulin-dependent Ca2+ Read more

Absorption

Information currently not available.

Protein binding

~75%

Volume of distribution

Within 15 to 30 minutes after injection, over 90% of the drug is distributed from the blood into tissue, where it remains tightly, but not irreversibly, bound.

Clearance

Information currently not available.

Half life

When intravenously injected into cancer patients, a triphasic serum decay patten was observed. The initial, middle, and terminal half-lives are 5 minutes, 2.3 hours, 85 hours respectively. The range of the terminal half-life is humans is 19 - 155 hours.

Route of elimination

The liver is the major excretory organ in humans and animals. 80% of an injected dose of vincristine sulfate is excreted via feces. 10 - 20% is excreted via urine.

Toxicity

IVN-RAT LD50 1300 mg/kg; IPR-MUS LD50 5.2 mg/kg. Marqibo® must only be administered IV because it is fatal if administered by other routes. Marqibo® also has different dosing than vincristine sulphate injection, so attention is needed to prevent overdoses. The most clinically s... Read more

Adverse Effects

Contraindications

  • Route:
    • Intravenous
  • Regions: US
  • Patient Conditions:
      • Name: Intrathecal administration
      • Drugbank Id: DBCOND0107822
  • Route:
    • Intravenous
  • Regions: US
  • Patient Conditions:
      • Name: Charcot-Marie-Tooth syndrome
      • Drugbank Id: DBCOND0107821
  • Route:
    • Intravenous
  • Regions: US
  • Patient Conditions:
      • Name: Demyelinating Disease
      • Drugbank Id: DBCOND0028403

Food Interactions

    Information currently not available.

Interactions

Type in a drug name to check for interaction with Vincristine
Type a drug name in the box above to get started
  • Paracetamol(acetaminophen)
  • Paxil(paroxetine)
  • Pamelor(nortriptyline)
  • Panadol(acetaminophen)
  • Patanol(olopatadine ophthalmic)
  • Pataday(olopatadine ophthalmic)
  • Parnate(tranylcypromine)
  • Pazeo(olopatadine ophthalmic)
2-Methoxyethanol
The risk or severity of adverse effects can be increased when Vincristine is combined with 2-Methoxyethanol.
6-Deoxyerythronolide B
The serum concentration of Vincristine can be increased when it is combined with 6-Deoxyerythronolide B.
9-(N-methyl-L-isoleucine)-cyclosporin A
The risk or severity of adverse effects can be increased when Vincristine is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Abatacept
The metabolism of Vincristine can be increased when combined with Abatacept.
Abemaciclib
Abemaciclib may decrease the excretion rate of Vincristine which could result in a higher serum level.
Abetimus
The risk or severity of adverse effects can be increased when Vincristine is combined with Abetimus.
Acalabrutinib
The metabolism of Vincristine can be decreased when combined with Acalabrutinib.
Acepromazine
Vincristine may increase the neurotoxic activities of Acepromazine.
Aceprometazine
Vincristine may increase the neurotoxic activities of Aceprometazine.
Acetophenazine
Vincristine may increase the neurotoxic activities of Acetophenazine.
Acetyldigitoxin
Acetyldigitoxin may decrease the cardiotoxic activities of Vincristine.
Acipimox
The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Vincristine is combined with Acipimox.
Acteoside
The risk or severity of adverse effects can be increased when Vincristine is combined with Acteoside.
Adalimumab
The metabolism of Vincristine can be increased when combined with Adalimumab.
Adenovirus type 7 vaccine live
The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Vincristine.
Afatinib
The excretion of Vincristine can be decreased when combined with Afatinib.
Afelimomab
The metabolism of Vincristine can be increased when combined with Afelimomab.
Aldesleukin
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Vincristine.
Aldosterone
The risk or severity of adverse effects can be increased when Vincristine is combined with Aldosterone.
Aldoxorubicin
The risk or severity of cardiotoxicity can be increased when Vincristine is combined with Aldoxorubicin.
4 References
  1. 1 . Graf WD, Chance PF, Lensch MW, Eng LJ, Lipe HP, Bird TD: Severe vincristine neuropathy in Charcot-Marie-Tooth disease type 1A. Cancer. 1996 Apr 1;77(7):1356-62.PubMed: 8608515
  2. 2 . Qweider M, Gilsbach JM, Rohde V: Inadvertent intrathecal vincristine administration: a neurosurgical emergency. Case report. J Neurosurg Spine. 2007 Mar;6(3):280-3.PubMed: 17355029
  3. 3 . JOHNSON IS, ARMSTRONG JG, GORMAN M, BURNETT JP Jr: THE VINCA ALKALOIDS: A NEW CLASS OF ONCOLYTIC AGENTS. Cancer Res. 1963 Sep;23:1390-427.PubMed: 14070392
  4. 4 . Gidding CE, Kellie SJ, Kamps WA, de Graaf SS: Vincristine revisited. Crit Rev Oncol Hematol. 1999 Feb;29(3):267-87.PubMed: 10226730